Back to Search Start Over

Higher small pulmonary artery and vein volume on computed tomography is associated with mortality in current and former smokers.

Authors :
Kwee AKAL
Andrinopoulou ER
van der Veer T
Gallardo-Estrella L
Charbonnier JP
Humphries SM
Lynch DA
Tiddens HAWM
de Jong PA
Pompe E
Source :
EBioMedicine [EBioMedicine] 2024 Oct; Vol. 108, pp. 105366. Date of Electronic Publication: 2024 Sep 30.
Publication Year :
2024

Abstract

Background: In chronic obstructive pulmonary disease (COPD), vascular alterations have been shown to contribute to hypoxia and pulmonary hypertension, but the independent contribution of small vessel abnormalities to mortality remains unclear.<br />Methods: We quantified artery and vein dimensions on computed tomography (CT) down to 0.2 mm. Small vessel volumes (<1 mmá´“) were normalized by body surface area. In 7903 current and former smokers of the COPDGene study (53.2% male) the independent contribution of small artery and small vein volume to all-cause mortality was tested in multivariable Cox models. Additionally, we calculated the 95 <superscript>th</superscript> percentile of small arteries and veins in 374 never smokers to create two groups: normal and high small artery or vein volume. We describe clinical, physiological and imaging characteristics of subjects with a high small artery and high small vein volume.<br />Findings: Both high small artery and high small vein volumes were independently associated with mortality with an adjusted hazard ratio of 1.07 [1.01, 1.14] and 1.34 [1.21, 1.49] per mL/m <superscript>2</superscript> increase, respectively. In COPDGene, 447 (5.7%) had high small artery volume and 519 (9.1%) subjects had high small vein volume and both had more emphysema, more air trapping and more severe coronary calcium.<br />Interpretation: In smokers, abnormally high volumes in small arteries and veins are both relevant for mortality, which urges investigations into the aetiology of small pulmonary vessels and cardiac function in smokers.<br />Funding: Award Number U01-HL089897 and U01-HL089856 from the NHLBI. COPD Foundation with contributions from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion.<br />Competing Interests: Declaration of interests AK, EA, TV, EP: no conflicts relevant to this manuscript. DL and SH: the department of radiology of National Jewish Health received grant support from the NHLBI. PdJ: The Department of Radiology from the UMC Utrecht receives research support from Philips Healthcare. JPC: employee and shareholder of Thirona. LGE, HT: employee of Thirona.<br /> (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2352-3964
Volume :
108
Database :
MEDLINE
Journal :
EBioMedicine
Publication Type :
Academic Journal
Accession number :
39353280
Full Text :
https://doi.org/10.1016/j.ebiom.2024.105366